title: Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
abstract: Dengue virus (DENV) is a human pathogen with a large impact on public health. Although no vaccine against DENV is currently licensed, a recombinant vaccine - chimeric yellow fever virus-DENV tetravalent dengue vaccine (CYD-TDV) - has shown efficacy against symptomatic dengue disease in two recent Phase III clinical trials. Safety observations were also recently reported for these trials. In this Opinion article, we review the data from recent vaccine clinical trials and discuss the putative mechanisms behind the observed efficacy of the vaccine against different forms of the disease, focusing on the interactions between the infecting virus, pre-existing host immunity and vaccine-induced immune responses.
authors.affiliation: Sanofi Pasteur, Research &Development, 2 Avenue du Pont Pasteur, 69007 Lyon, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Guy
authors.affiliation: Sanofi Pasteur, Research &Development, 2 Avenue du Pont Pasteur, 69007 Lyon, France.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Jackson
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology*; D003716:Dengue Virus / Q000276:immunology*; D004337:Drug Carriers; D006801:Humans; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000276:immunology; D015005:Yellow fever virus / Q000235:genetics
chemical_list: D053059:Dengue Vaccines; D004337:Drug Carriers; D014614:Vaccines, Synthetic